Bristol Myers Squibb Co. shares surged on Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug.

AbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet ... However, Bristol Myers’ BMY stock was up 10.5% following ABBV’s news. The studies were designed to ...

shares surged on Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug. Bristol Myers's stock (BMY) was up more than 11% in afternoon trading ...